Annual Report 2005 - Boehringer Ingelheim

More documents

Recommendations

Info

10 Our commitment We have committed ourselves to the goal of serving mankind through research into diseases and the development of new drugs and therapies. In this endeavour the future of the Corporation will depend on its innovative capability. Boehringer Ingelheim strives for medical breakthroughs and invests heavily in research, development and medicine for therapies which fulfil unmet medical needs. In improving access to anti-AIDS drugs, Boehringer Ingelheim acknowledges its special responsibility as a research-driven pharmaceutical company in the war on the pandemic. It is engaged in wide-ranging initiatives to combat AIDS. The company has increased efforts in HIV/AIDS research, in supplying anti-AIDS drugs free of charge to treat the transmission of the disease from mother-to-child during birth, or providing them at substantially reduced prices to developing countries for chronical treatment. It has furthermore increased its activities supplying knowledge and training and supporting philanthropic initiatives via its affiliates in areas strongly affected by HIV/AIDS. Since 2000, Boehringer Ingelheim has given free access to single-dose viramune® (nevirapine), to be used alone or in combination with other drugs, to prevent mother-to-child transmission of the HI virus during birth. The company currently donates the product to some 140 programmes in around 60 countries in Africa, Asia, Latin America and Eastern Europe. In total some 700,000 mother and child pairs have been treated so far. Boehringer Ingelheim A n n u A l R e p o R t 2 0 0 5 Boehringer Ingelheim strives to facilitate the access to life-saving nevirapine. Five voluntary licenses to manufacture and market generic nevirapine have been granted to companies in South Africa, Nigeria, Egypt and Kenya. Moreover, as a founding partner of the Accelerat- ing Access Initiative (AAI), Boehringer Ingelheim offers developing countries considerable dis- counts in order to enable access to viramune®. Some 6,000 of Papua New Guinea’s 5.3 million inhabitants are infected with HIV and the infection rate is 1,000 per year. Very few infected people go to healthcare centres so the figures are likely to be vastly underestimated. Apart from the viramune® Donation Programme, Boehringer Ingelheim in partnership with other pharmaceutical companies, the Catholic Aids Office, the Australasian Society for HIV Medicine (ASHM) and the government of Papua New Guinea (PNG), have designed and implemented a pilot project to train healthcare workers under the auspices of the Collaboration for Health in Papua New Guinea. Unlike other programmes, this model used a multi-disciplinary approach to train teams of healthcare workers rather than doctors only.
Uganda has made strong progress in reducing the prevalence rate of HIV. The key to this success has been public openness, at all levels of society, in addressing the issue. Here, people living with HIV in Uganda demonstrate their support for treatment at the opening of a free AIDS clinic in Masaka, close to where the pandemic is thought to have begun. The teams consisted of physicians, nurses, counsellors, social workers and technicians working in healthcare centres. Topics covered in workshops included basic infection control, infection prevention, record keeping, diagnosis and management of opportunistic infections. The collaboration for Health in PNG is an initiative of a group of pharmaceutical manufacturers committed to the treatment and care of people living with HIV/AIDS. Addressing infrastructure needs As improving access to treatment remains seriously limited in many developing countries due to local structural problems in healthcare, Boehringer Ingelheim has also engaged increas- ingly in projects to improve education and relevant infrastructure. In addition to donation and increasing access to drugs, the company continues to explore ways to partner governments and NGOs to improve healthcare in developing countries. Initiatives the company has already undertaken in South Africa include the “Turning the Tide” programme of training and education for health professionals in HIV and its management. This has been extended into Swaziland and Botswana and now reaches over 1,000 healthcare workers. In 2005, Boehringer Ingelheim opened discus- sions with healthcare organisations in Uganda with a view to possibly replicating schemes which have been successful in other parts of Africa. Among other initiatives was the Student Education Programme in collaboration with the University of Cape Town, South Africa, which provides full financial support from Boehringer Ingelheim for medical students from disadvan- taged backgrounds. The Boehringer Ingelheim Lung Institute at the same university has been set up as a centre of excellence to support clinical trial activities in the country with research facilities in infectious and respiratory diseases. In 2005, the Boehringer Ingelheim Training and Facilitation Unit was opened in Botswana. Our commitment 11
Page 1 and 2: Value through Innovation Annual Rep
Page 3 and 4: Contents 2 The Shareholders’ Pers
Page 5 and 6: Value through Innovation Our vision
Page 7 and 8: of innovative medications. Our expe
Page 9 and 10: countries since 2000 encourages us
Page 11: Shareholders’ Committee Dr Heribe
Page 16 and 17: 1 For our neighbours We are fundame
Page 18 and 19: 1 For our people To achieve our cor
Page 20 and 21: 1 We foster good leadership at all
Page 22 and 23: 1 For our environment In all our ac
Page 24 and 25: 0 Assessments to date show that our
Page 27 and 28: Our R&D drive Holger Pfister has be
Page 29 and 30: New data presented at the 10th Euro
Page 31 and 32: Thanks to new treatments and innova
Page 33 and 34: Laboratory assistants at our Qualit
Page 35 and 36: In addition, our discovery efforts
Page 37 and 38: the age of 65 combined with an agin
Page 39 and 40: Clinical development and registrati
Page 41 and 42: increase the planned patient number
Page 43: Business Development Our Businesses
Page 46 and 47: “spiriva® has obviously improved
Page 48 and 49: Prescription Medicines Boehringer I
Page 50 and 51: Protection around the clock “In t
Page 52 and 53: Stroke treatment and prevention Str
Page 54 and 55: 0 Serotonin and norepinephrine also
Page 56 and 57: Rheumatologic diseases Osteoarthrit
Page 58 and 59: Asia, Australasia, Africa In all ma
Page 60: Consumer Health Care Let’s talk a
Page 63 and 64: Gentle and effective dulcolax® for
Page 65 and 66:
health market. With sales of almost
Page 67 and 68:
is critical
Page 69 and 70:
at the end of the 1970s with the ma
Page 71 and 72:
Moreover, for Boehringer Ingelheim
Page 73 and 74:
Pioneering college course in biotec
Page 75 and 76:
heartWhen her Labrador Buster fell
Page 77 and 78:
According to the American Veterinar
Page 79 and 80:
Cattle There were two highly gratif
Page 81 and 82:
Group Management Report
Page 83 and 84:
and strength of the group. The grea
Page 85 and 86:
cymbalta®, the anti-depressive in-
Page 87 and 88:
Components of growth in net sales (
Page 89 and 90:
Worldwide growth was achieved by th
Page 91 and 92:
Liquid assets declined by 12 % comp
Page 93 and 94:
Consolidated Financial Statements 2
Page 95 and 96:
C. H. Boehringer Sohn Grundstücksv
Page 97 and 98:
C. H. Boehringer Sohn, Ingelheim Co
Page 99 and 100:
C. H. Boehringer Sohn, Ingelheim St
Page 101 and 102:
The following subsidiaries were exe
Page 103 and 104:
2 Accounting and evaluation methods
Page 105 and 106:
3 Notes to the consolidated balance
Page 107 and 108:
3.3 Financial assets (in millions o
Page 109 and 110:
Pension provisions Boehringer Ingel
Page 111 and 112:
4 Notes to the consolidated profit
Page 113 and 114:
4.7 Holding income (in millions of
Page 115 and 116:
Other mandatory disclosures accordi
Page 117 and 118:
Derivative financial instruments at
Page 119 and 120:
With the following exception, our a
Page 121 and 122:
Product name Active ingredient Indi
Page 123 and 124:
Animal Health Product name Active i
Page 125 and 126:
Comparison of Balance Sheets/ Finan
show all

Annual Report 2005 - Boehringer Ingelheim

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?